BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ventria Bioscience Launches Lacromin(TM) A Plant-Derived Growth Factor For Cell Culture Media


10/19/2005 5:11:57 PM

SACRAMENTO, Calif., July 19 /PRNewswire/ -- Ventria Bioscience has announced the introduction of a new plant-derived recombinant growth factor for cell culture media that improves productivity and safety. Lacromin(TM) is a strong growth factor and outperforms Transferrin, a common animal-derived growth factor. Lacromin(TM) was introduced today at the "Raw Materials and Disposable Process Systems for Mammalian Cell Products Conference" in Kansas City, Missouri.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020404/SFTH029LOGO )

"We are excited about Lacromin(TM) to improve the productivity and safety of cell culture manufacturing," said Scott Deeter, President and CEO, Ventria Bioscience. "Given the FDA's preference for non-animal derived cell culture media ingredients, plant-derived proteins like Lacromin(TM) are a real breakthrough for this market."

"We are very encouraged by the positive results we have generated on Lacromin(TM)," said Ning Huang, Vice President of Research and Development, Ventria Bioscience. "At the conference today, I presented results showing Lacromin(TM) significantly increased the productivity of antibody production when compared with animal-derived transferrin."

Ventria Bioscience will market Lacromin(TM) to companies that seek a serum-free and animal component free cell culture media source for their biopharmaceutical production.

About Lacromin(TM)

Lacromin(TM) is recombinant human lactoferrin derived from plants. Lacromin(TM) holds many advantages over current cell culture media ingredients:

* Strong growth factor Lacromin(TM) has been shown to promote cell growth in many cell lines, including Chinese Hamster Ovary (CHO) cells and Mouse Hybridoma cells. * Outperforms Transferrin Lacromin(TM) promotes higher cell density and reduces cell doubling time when compared with Transferrin. * Replaces Animal Derived Transferrin Since Lacromin(TM) is derived from plants, it is free of any viral or prion contaminant risks. * Improves IgG Productivity In Hybridoma cells, Lacromin(TM) increased IgG productivity by 50% versus Transferrin and by 6% versus Fetal Bovine Serum (FBS).

Lacromin(TM) is offered for sale from Ventria Bioscience in 100 gram, 1 kilogram and 5 kilogram quantities. Pricing of Lacromin(TM) is available upon request.

About Ventria Bioscience

Ventria Bioscience is a biopharmaceutical company commercializing products that enhance human health. In addition to Lacromin(TM) for the cell culture market, Ventria has several products in development for human health applications.

For more information about Ventria Bioscience, see our website at http://www.ventria.com

Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.

Photo: http://www.newscom.com/cgi-bin/prnh/20020404/SFTH029LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comVentria Bioscience

CONTACT: Brandy Sargent, +1-916-921-6148, or info@ventria.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES